Testosterone Therapy in Older Men: Present and Future Considerations DOI Creative Commons
Bu B. Yeap, Cammie Tran,

Catherine M. Douglass

и другие.

Drugs & Aging, Год журнала: 2025, Номер unknown

Опубликована: Апрель 27, 2025

Testosterone is the classical male anabolic hormone, involved in sexual development, virilisation and regulation of body composition adult men. Organic disease involving hypothalamus, pituitary or testes may interfere with endogenous testosterone production. In such men, treatment effectively ameliorates symptoms signs androgen deficiency. However, non-gonadal factors including age, mass index medical comorbidities influence circulating testosterone, older men have on average lower concentrations compared younger these would be a pharmacological intervention requiring stringent justification via high-quality evidence from randomised controlled trials (RCTs). Recent RCTs show benefits to improve function, anaemia bone mineral density prevent revert type 2 diabetes mellitus at high risk. Results large cardiovascular safety trial risk provide important reassurance as prostate treatment. Key questions remain whether testosterone's other effects can used safely counter reductions lean associated incretin-based weight loss medications obesity, it might disabilities frailty, osteoporotic fractures dementia generally. This last question could answered by new RCT, targeting 65-80 years age bracket, which necessarily extended duration. A composite endpoint integrates potential risks, disability-free survival.

Язык: Английский

Testosterone Therapy in Older Men: Present and Future Considerations DOI Creative Commons
Bu B. Yeap, Cammie Tran,

Catherine M. Douglass

и другие.

Drugs & Aging, Год журнала: 2025, Номер unknown

Опубликована: Апрель 27, 2025

Testosterone is the classical male anabolic hormone, involved in sexual development, virilisation and regulation of body composition adult men. Organic disease involving hypothalamus, pituitary or testes may interfere with endogenous testosterone production. In such men, treatment effectively ameliorates symptoms signs androgen deficiency. However, non-gonadal factors including age, mass index medical comorbidities influence circulating testosterone, older men have on average lower concentrations compared younger these would be a pharmacological intervention requiring stringent justification via high-quality evidence from randomised controlled trials (RCTs). Recent RCTs show benefits to improve function, anaemia bone mineral density prevent revert type 2 diabetes mellitus at high risk. Results large cardiovascular safety trial risk provide important reassurance as prostate treatment. Key questions remain whether testosterone's other effects can used safely counter reductions lean associated incretin-based weight loss medications obesity, it might disabilities frailty, osteoporotic fractures dementia generally. This last question could answered by new RCT, targeting 65-80 years age bracket, which necessarily extended duration. A composite endpoint integrates potential risks, disability-free survival.

Язык: Английский

Процитировано

0